DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 765080

First Posted Date: 2021-10-13

Last Posted Date: 2024-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT05075772

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 425809
Drug: fluconazole

First Posted Date: 2021-10-13

Last Posted Date: 2022-01-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT05076409

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test How Well Men Tolerate Different Doses of BI 3006337

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 3006337

First Posted Date: 2021-10-13

Last Posted Date: 2023-03-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 80

Registration Number: NCT05076422

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
🇳🇱
ICON, Groningen, Netherlands

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Phase 1

Recruiting

Conditions: Carcinoma, Squamous Cell of Head and Neck (HNSCC)
Melanoma
Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Ezabenlimab
Drug: BI 765063
Drug: BI 770371
Drug: [89Zr]Zr- BI 765063
Drug: [89Zr]Zr- BI 770371

First Posted Date: 2021-10-05

Last Posted Date: 2025-04-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 13

Registration Number: NCT05068102

Locations: 🇳🇱
VU University Medical Center, Amsterdam, Netherlands

A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis

Phase 3

Completed

Conditions: Lung Diseases, Interstitial

Interventions: Drug: Nintedanib
Drug: Placebo

First Posted Date: 2021-10-01

Last Posted Date: 2025-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 81

Registration Number: NCT05065190

Locations: 🇨🇳
China-Japan Friendship Hospital, Beijing, China
🇨🇳
The Second Hospital of Jilin University, Changchun, China
🇨🇳
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

and more 13 locations

A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin

Completed

Conditions: Coronary Artery Disease
Atrial Fibrillation

First Posted Date: 2021-09-21

Last Posted Date: 2024-03-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 39357

Registration Number: NCT05051904

Locations: 🇩🇪
Boehringer Ingelheim - International GmbH, Ingelheim am Rhein, Germany

Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Nintedanib

First Posted Date: 2021-08-26

Last Posted Date: 2024-04-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1798

Registration Number: NCT05022784

Locations: 🇺🇸
Medicus Economics, LCC, Milton, Massachusetts, United States

A Study to Test Whether Spesolimab Helps People With Crohn's Disease Who Have Symptoms of Bowel Obstruction

Phase 2

Terminated

Conditions: Fibrostenotic Crohn´s Disease

Interventions: Drug: Placebo
Drug: Spesolimab

First Posted Date: 2021-08-19

Last Posted Date: 2025-02-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 5

Registration Number: NCT05013385

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇨🇦
Heritage Medical Research Clinic, Calgary, Alberta, Canada
🇸🇪
Sahlgrenska Universitetssjukhuset, Mölndal, Mölndal, Sweden

and more 1 locations

A Study in Healthy Men to Test How Well Different Doses of BI 1569912 Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1569912
Drug: Placebo

First Posted Date: 2021-07-27

Last Posted Date: 2025-01-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 83

Registration Number: NCT04978506

Locations: 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

Phase 2

Terminated

Conditions: Crohn Disease

Interventions: Drug: BI 706321
Drug: ustekinumab
Drug: Placebo

First Posted Date: 2021-07-27

Last Posted Date: 2024-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 49

Registration Number: NCT04978493

Locations: 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Southern Star Research Institute, LLC, San Antonio, Texas, United States
🇺🇸
University of Utah Health Sciences Center, Salt Lake City, Utah, United States

and more 46 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy